The Medical Letter - 2014
Year:    Publication:      2014 Annual Index: U.S. English | Canadian English
January 6, 2014 (Issue 1433)  
January 20, 2014 (Issue 1434)  
  • Sofosbuvir (Sovaldi) for Chronic Hepatitis C
    The FDA has approved the nucleotide polymerase inhibitor sofosbuvir (Sovaldi – Gilead) for use in combination with other antiviral drugs for treatment of chronic hepatitis C virus (HCV)...
  • Antiviral Drugs for Influenza 2013-2014
    Superseded by The Medical Letter "Antiviral Drugs for Seasonal Influenza 2017-2018" - Issue 1537, January 1, 2018Antiviral drugs can be used for treatment of influenza and as an adjunct to...
  • In Brief: Ponatinib (Iclusig) Returns
    The October 2013 suspension of marketing and sales of ponatinib (Iclusig – Ariad) for treatment of leukemia1 has been lifted by the FDA, and the drug is expected to return to the market...
February 3, 2014 (Issue 1435)  
February 17, 2014 (Issue 1436)  
March 3, 2014 (Issue 1437)  
  • In Brief: Testosterone and Cardiovascular Risk
    Prompted by the recent publication of 2 retrospective studies, the FDA has announced that it is investigating the risk of stroke, heart attack, and death in men taking FDA-approved testosterone...
  • Riociguat (Adempas) for Pulmonary Hypertension
    The FDA has approved the sGC stimulator riociguat (rye" oh sig' ue at; Adempas – Bayer) for oral treatment of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary...
  • Low-Dose Diclofenac (Zorvolex) for Pain
    The FDA has approved Zorvolex (Iroko), a low-dose oral formulation of the relatively COX-2 selective NSAID diclofenac, for treatment of mild-to-moderate acute pain in adults.
March 17, 2014 (Issue 1438)  
  • Mumps Outbreak
    An outbreak of mumps has occurred among students at Fordham University in New York. All of those who developed mumps had been vaccinated against the disease.
  • Intranasal Naloxone for Treatment of Opioid Overdose
    The recent increase in deaths from heroin overdose in the US has led to renewed interest in the opioid antagonist naloxone, particularly in making it available as an intranasal spray to...
  • Drugs for Gout
    The goals of gout treatment are threefold: treating acute inflammation, preventing flares, and lowering serum urate levels.
March 31, 2014 (Issue 1439)  
April 14, 2014 (Issue 1440)  
April 28, 2014 (Issue 1441)  
May 12, 2014 (Issue 1442)  
May 26, 2014 (Issue 1443)  
  • Apremilast (Otezla) for Psoriatic Arthritis
    Apremilast (Otezla – Celgene), an oral phosphodiesterase type-4 (PDE4) inhibitor, has been approved by the FDA for treatment of active psoriatic arthritis in adults. It is the fi rst...
  • Eslicarbazepine Acetate (Aptiom) for Epilepsy
    Eslicarbazepine acetate (Aptiom – Sunovion) has been approved by the FDA for adjunctive treatment of partial-onset seizures in adults. New drugs for epilepsy are often approved by the...
  • Sorafenib (Nexavar) for Thyroid Cancer
    The FDA has approved the use of the oral multikinase inhibitor sorafenib (Nexavar – Bayer) for treatment of locally recurrent or metastatic, progressive, differentiated thyroid cancer...
  • In Brief: Heptavalent Botulism Antitoxin
    The FDA has approved the use of an equine heptavalent botulism antitoxin (BAT, Cangene Corporation). The new antitoxin includes antibodies against all 7 botulinum neurotoxin types (A-G). A...
June 9, 2014 (Issue 1444)  
  • In Brief: A Naloxone Auto-Injector (Evzio)
    A recent Medical Letter article reported renewed interest in the intranasal administration (off-label) of the opioid antagonist naloxone because of an increase in deaths from opioid overdose in the...
  • Extended-Release Hydrocodone (Zohydro ER) for Pain
    The FDA has approved an extended-release oral formulation of the opioid agonist hydrocodone (Zohydro ER – Zogenix) for management of pain severe enough to require continuous, long-term...
  • Sublingual Immunotherapy for Allergic Rhinitis
    The FDA has approved 3 allergen extracts for sublingual administration as immunotherapy for allergic rhinitis confirmed by a positive skin test or in vitro testing for pollen-specific IgE...
  • In Brief: Lowering the Dose of Lunesta
    The FDA has required the manufacturer of eszopiclone (Lunesta – Sunovion), a benzodiazepine receptor agonist approved for the treatment of insomnia, to lower the current recommended...
June 23, 2014 (Issue 1445)  
July 7, 2014 (Issue 1446)  
  • Treatment of Atrial Fibrillation
    The treatment of atrial fibrillation includes anticoagulation, rate control, and rhythm control. New US guidelines for the management of atrial fibrillation have recently been published.
July 21, 2014 (Issue 1447)  
August 4, 2014 (Issue 1448)  
  • Drugs for Inflammatory Bowel Disease
    Aminosalicylates are effective for induction and maintenance of remission in mild to moderate ulcerative colitis. They are not recommended for treatment of Crohn's disease. FORMULATIONS...
August 18, 2014 (Issue 1449)  
September 1, 2014 (Issue 1450)  
  • Statins and Diabetes Risk
    In 2012, the FDA required manufacturers of HMG-CoA reductase inhibitors (statins) to add a warning to their labels about reports of increased blood glucose and glycosylated hemoglobin (HbA1c)...
  • Drugs for Osteoarthritis
    Many different drugs are used for treatment of osteoarthritis pain, but none of them prevent progression of the disease. Many nonpharmacologic approaches are available as well, including weight...
  • In Brief: New Polio Vaccination Guidance for Travelers
    Wild poliovirus has circulated during the previous 12 months in Cameroon, Equatorial Guinea, Ethiopia, Iraq, Israel (also the West Bank and Gaza), Somalia, and Syria, as well as in those countries...
September 15, 2014 (Issue 1451)  
September 29, 2014 (Issue 1452)  
  • Drugs for Postmenopausal Osteoporosis
    Superseded by The Medical Letter "Drugs for Postmenopausal Osteoporosis" - Issue 1536, December 18, 2017US guidelines for the treatment of osteoporosis have been published. The diagnosis of...
October 13, 2014 (Issue 1453)  
October 27, 2014 (Issue 1454)  
  • Antithrombotic Drugs
    Antiplatelet drugs are the drugs of choice for prevention and treatment of arterial thrombosis. Anticoagulants are the drugs of choice for prevention and treatment of venous thromboembolism and...
November 10, 2014 (Issue 1455)  
November 24, 2014 (Issue 1456)  
  • Vaccines for Travelers
    Patients planning to travel to other countries should be up to date on routine immunizations and, depending on their destination, duration of travel, and planned activities, may also need to...
December 8, 2014 (Issue 1457)  
December 22, 2014 (Issue 1458)